Skip to main content

Table 1 Patient characteristics

From: Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking

Total patients

(n = 39)

Age

  
 

≤ 69 years

20 (51.3%)

 

> 69 years

19 (48.7%)

Tumor stage

  
 

cT1

12 (30.8%)

 

cT2

5 (12.8%)

 

cT3a

13 (33.4%)

 

cT3b

7 (17.9%)

 

cT4

2 (5.1%)

Gleason score

  
 

2–6

20 (51.3%)

 

7

13 (33.3%)

 

8–10

6 (15.4%)

Pre-treatment PSA

  
 

≤ 10 ng/mL

20 (51.3%)

 

>10 ng/mL

19 (48.7%)

Risk group

  
 

Low

7 (17.9%)

 

Intermediate

8 (20.5%)

 

High

24 (61.6%)

Hormonal therapy

  
 

no

10 (25.6%)

 

yes

29 (74.4%)

Median FU months† (range)

 

29 (22–40)

  1. Abbreviations: PSA = prostate- specific antigen; FU = follow-up;
  2. †period after completion of treatment.